Harvard Bioscience (HBIO) Net Margin (2010 - 2026)

Harvard Bioscience (HBIO) has 16 years of Net Margin data on file, last reported at 16.5% in Q1 2026.

• On a quarterly basis, Net Margin rose 21448.0% year-over-year to 16.5% in Q1 2026; TTM through Mar 2026 was 11.41%, a 5167.0% increase from a year earlier, with the FY2025 full-year figure at 65.51%, down 5266.0% from the prior year.
• Net Margin for Q1 2026 stood at 16.5%, down from 11.87% in the prior quarter.
• Over the last five years, Net Margin for HBIO reached as high as 8.34% in Q2 2022 and fell as low as 230.98% in Q1 2025.
• Historically, Net Margin has averaged 21.81% across 5 years, with a median of 11.17% in 2025.
• Across the five-year window, Net Margin sank 21183 bps in 2025 and jumped 21448 bps in 2026, its largest moves.
• Year by year, Net Margin stood at 5.86% in 2022, then surged by 72 bps to 1.66% in 2023, then soared by 189 bps to 1.47% in 2024, then sank by 910 bps to 11.87% in 2025, then plunged by 39 bps to 16.5% in 2026.
• Per Business Quant data, the three most recent Net Margin figures were 16.5% in Q1 2026, 11.87% in Q4 2025, and 5.98% in Q3 2025.